Department of Anesthesiology, Renmin Hospital of Wuhan University, No.238 Jiefang Road, Wuchang District, Wuhan, 430060, China.
Organ Transplantation Center, Tianjin First Central Hospital, Tianjin, 300192, China.
Inflamm Res. 2022 Dec;71(12):1463-1476. doi: 10.1007/s00011-022-01651-6. Epub 2022 Oct 25.
Ischemia and reperfusion injury (IRI) is an ineluctable immune-related pathophysiological process during organ transplantation, which not only causes a shortage of donor organs, but also has long-term and short-term negative consequences on patients. Severe IRI-induced cell death leads to the release of endogenous substances, which bind specifically to receptors on immune cells to initiate an immune response. Although innate and adaptive immunity have been discovered to play essential roles in IRI in the context of organ transplantation, the pathway and precise involvement of the immune response at various stages has not yet to be elucidated.
We combined "IRI" and "organ transplantation" with keywords, respectively such as immune cells, danger signal molecules, macrophages, neutrophils, natural killer cells, complement cascade, T cells or B cells in PubMed and the Web of Science to search for relevant literatures.
Comprehension of the immune mechanisms involved in organ transplantation is promising for the treatment of IRI, this review summarizes the similarities and differences in both innate and adaptive immunity and advancements in the immune response associated with IRI during diverse organ transplantation.
缺血再灌注损伤(IRI)是器官移植过程中不可避免的免疫相关病理生理过程,不仅导致供体器官短缺,而且对患者产生长期和短期的负面影响。严重的 IRI 诱导的细胞死亡导致内源性物质的释放,这些物质特异性地与免疫细胞上的受体结合,从而引发免疫反应。尽管在器官移植的背景下已经发现固有免疫和适应性免疫在 IRI 中发挥重要作用,但免疫反应在各个阶段的途径和确切参与尚未阐明。
我们分别在 PubMed 和 Web of Science 中使用“IRI”和“器官移植”与免疫细胞、危险信号分子、巨噬细胞、中性粒细胞、自然杀伤细胞、补体级联、T 细胞或 B 细胞等关键词相结合,搜索相关文献。
理解器官移植中涉及的免疫机制有望治疗 IRI,本综述总结了不同器官移植中 IRI 相关固有免疫和适应性免疫以及免疫反应的异同。